ECM
CRSP icon

Elgethun Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Elgethun Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-300
Closed -$6K – 106
2016
Q4 		$6K Buy
+300
New +$5.61K ﹤0.01% 230

Other funds holding CRSP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Elgethun Capital Management's CRSP Position: Q1 2017 in Review

Elgethun Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2017, closing a stake of 300 shares — an estimated $6K sold.

Elgethun Capital Management first reported a position in CRSP in Q4 2016 and held it in 1 quarter. The position peaked at $6K in Q4 2016. 35 funds tracked by Wall St. Rank hold CRSP as of Q1 2017.

  • Elgethun Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Elgethun Capital Management sold 300 CRISPR Therapeutics shares in Q1 2017, an estimated $6K.
  • Elgethun Capital Management first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 1 quarter.
  • Elgethun Capital Management's CRISPR Therapeutics position peaked at $6K in Q4 2016.
  • 35 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2017.

Based on Elgethun Capital Management's 13F filing for Q1 2017, filed 11 May 2017.